5 Results for "

C2C12 myoblasts/myotubes

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "C2C12 myoblasts/myotubes" in MCE Product Catalog:

Cat. No.: HY-P10646
CAS No.: 2896181-32-9
Target:  

Inhibitory Antibodies

Research Areas:  

Others

Muscle homing peptide M12 is a muscle-homing peptide with high affinity for skeletal muscle and cardiac muscle. Muscle homing peptide M12 can mediate the targeted delivery of loaded drugs to skeletal muscle and cardiac muscle tissues .
loading...
    loading...
Cat. No.: HY-102052
CAS No.: 60563-36-2
Purity:  99.25%
Target:  

Potassium Channel

Research Areas:  

Metabolic Disease

DCEBIO is a small/medium conductance calcium-activated potassium (SKCa/IKCa) channel opener and primary neuron signal blocker. It hyperpolarizes the membrane potential of C2C12 myoblasts by activating IKCa channels, thereby promoting myogenic differentiation. The specific biological activity of DCEBIO is manifested in increased myotube formation, enhanced myosin heavy chain II protein levels and myogenin mRNA levels. DCEBIO can be applied in the field of muscle research, especially in muscle-related degenerative diseases such as sarcopenia .
loading...
    loading...
Cat. No.: HY-N3741
CAS No.: 18296-45-2
Synonyms: Didrovaltratum
Didrovaltrate (Didrovaltratum) is an L-type calcium channel blocker, ROS scavenger, autophagy enhancer, and lipid accumulation inhibitor. Didrovaltrate blocks L-type calcium currents in a concentration-dependent manner, shifts the current-voltage curve upward, modulates steady-state inactivation kinetics, and inhibits the nuclear translocation of glucocorticoid receptors. Didrovaltrate reduces ROS levels, downregulates the expression of muscle atrophy-related genes, enhances autophagy via lipophagy, and decreases Oleic acid-induced lipid accumulation. Didrovaltrate exhibits cytotoxic activity against cancer cells. Didrovaltrate can be used in research related to skeletal muscle atrophy, non-alcoholic fatty liver disease, breast cancer, lung cancer, gastric cancer, and prostate cancer .
loading...
    loading...
Cat. No.: HY-130645
CAS No.: 2410557-01-4
Target:  

PROTACs PARP

Research Areas:  

Cancer

iRucaparib-TP3 is a non-trapping PARP1 PROTAC degrader with concurrent PARP1 catalytic inhibitory activity. iRucaparib-TP3 induces PARP1 ubiquitination and subsequent proteasomal degradation. iRucaparib-TP3 can be used for the research of cervical adenocarcinoma .
loading...
    loading...
Cat. No.: HY-102052R
CAS No.: 60563-36-2
Research Areas:  

Metabolic Disease

DCEBIO (Standard) is the analytical standard of DCEBIO (HY-102052). This product is intended for research and analytical applications. DCEBIO is a small/medium conductance calcium-activated potassium (SKCa/IKCa) channel opener and primary neuron signal blocker. It hyperpolarizes the membrane potential of C2C12 myoblasts by activating IKCa channels, thereby promoting myogenic differentiation. The specific biological activity of DCEBIO is manifested in increased myotube formation, enhanced myosin heavy chain II protein levels and myogenin mRNA levels. DCEBIO can be applied in the field of muscle research, especially in muscle-related degenerative diseases such as sarcopenia .
loading...
    loading...